Equity · Healthcare
REGN
NASDAQRegeneron Pharmaceuticals (REGN)
The line runs 829 USD on 24 August through 921.31 USD on 20 November, on a scale from 700 to 1,000. Days the market did not trade hold the previous close, flat.
- Market cap
- 97.9B USD
- P/E (TTM)
- 20.4
- Revenue, year to Dec 2025
- 14.3B USD
- EPS, diluted, year to Dec 2025
- 41.48 USD
- 52-week range
- 600 USD – 973.81 USD
- Avg volume
- 49.0K
- Mentions, 30 days
- 7
- Net sentiment
- +0.18
as of Nov 20, 2026
Have Regeneron Pharmaceuticals (REGN) insiders bought or sold shares recently?
In the 90 days to 23 Nov 2026, Regeneron Pharmaceuticals insiders reported 16 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Aug 2026, show no open-market purchase.
Form 4, 90 days to 23 Nov 2026, newest reported trade 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Sell | 5,011 | 4.8M USD |
| 17 Nov 2026 | SING GEORGE LDirector | Sell | 1,000 | 958K USD |
| 16 Nov 2026 | McCourt MarionEVP Commercial | Sell | 566 | 544K USD |
| 16 Nov 2026 | SING GEORGE LDirector | Sell | 1,000 | 960K USD |
| 04 Nov 2026 | Pitofsky JasonSVP Controller | Sell | 4,062 | 3.8M USD |
| 03 Nov 2026 | Zoghbi Huda YDirector | Sell | 7,439 | 7.2M USD |
| 02 Nov 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Sell | 4,466 | 4.3M USD |
| 02 Nov 2026 | POON CHRISTINE ADirector | Sell | 7,830 | 7.6M USD |
| 02 Nov 2026 | SING GEORGE LDirector | Sell | 21,129 | 20.4M USD |
| 30 Oct 2026 | BROWN MICHAEL SDirector | Sell | 1,929 | 1.7M USD |
| 30 Oct 2026 | Guarini KathrynDirector | Sell | 400 | 360K USD |
| 30 Oct 2026 | McCourt MarionEVP Commercial | Sell | 1,132 | 984K USD |
| Sold | 16 open-market sales | 62,857 | $59.16M |
Showing the 12 most recent of 16 open-market trades in this window. The figures above count all of them.
17 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Nov 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Option exercise | 17,000 | 6.5M USD |
| 16 Nov 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Tax withheld | 11,989 | 11.5M USD |
| 04 Nov 2026 | Pitofsky JasonSVP Controller | Option exercise | 3,883 | 2.5M USD |
| 03 Nov 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Gift | 1,054 | |
| 03 Nov 2026 | Zoghbi Huda YDirector | Option exercise | 7,439 | 2.8M USD |
| 02 Nov 2026 | Fenimore Christopher R.EVP Finance CFO | Option exercise | 6,000 | 2.3M USD |
| 02 Nov 2026 | Fenimore Christopher R.EVP Finance CFO | Tax withheld | 4,243 | 4.0M USD |
| 02 Nov 2026 | Fenimore Christopher R.EVP Finance CFO | Gift | 15 | |
| 02 Nov 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Option exercise | 12,283 | 4.7M USD |
| 02 Nov 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Tax withheld | 8,686 | 8.3M USD |
| 02 Nov 2026 | POON CHRISTINE ADirector | Option exercise | 7,830 | 2.9M USD |
| 02 Nov 2026 | SING GEORGE LDirector | Option exercise | 15,269 | 5.8M USD |
Showing the 12 most recent of 17 compensation filings in this window. The figures above count all of them.
Which funds hold Regeneron Pharmaceuticals (REGN)?
15 of the 45 institutional funds we track reported a Regeneron Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 2.9B USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 1,311,729 | 978.9M USD | +16.5% |
| Two Sigma Investments | Added | 869,505 | 659.3M USD | +32.5% |
| Citadel Advisors | Added | 352,728 | 267.5M USD | +512.3% |
| Man Group | Trimmed | 295,111 | 223.8M USD | −32.5% |
| Renaissance Technologies | Added | 272,218 | 206.4M USD | +83.7% |
| Marshall Wace | Added | 213,937 | 162.2M USD | +830.2% |
| Millennium Management | Held (±25%) | 147,538 | 111.9M USD | −10.6% |
| Point72 Asset Management | New position | 124,380 | 94.3M USD | |
| Bridgewater Associates | Added | 105,934 | 80.3M USD | +106.4% |
| D. E. Shaw & Co. | Added | 58,636 | 44.5M USD | +52.4% |
Showing the 10 largest of 15 reported positions. The figures above count all of them.
Have members of Congress traded Regeneron Pharmaceuticals (REGN)?
The most recent congressional trade disclosed in Regeneron Pharmaceuticals is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 May 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 15 May 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 24 days |
| 18 Nov 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 27 days |
| 15 May 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Purchase | 1K USD–15K USD | 25 days |
| 10 Apr 2025 | Byron Donaldshouse · Republican–FL | Sale | 1K USD–15K USD | 44 days |
| 08 Apr 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | 1K USD–15K USD | 30 days |
| 07 Apr 2025 | Jefferson Shrevehouse · Republican–IN | Sale | 15K USD–50K USD | 31 days |
| 01 Apr 2025 | Julie Johnsonhouse · Democrat–TX | Sale | 1K USD–15K USD | 43 days |
| 25 Feb 2025 | Robert P. Bresnahan, Jr.house · Republican–PA | Sale | 1K USD–15K USD | 30 days |
Regeneron Pharmaceuticals (REGN) US federal contracts
US federal agencies committed 279.4M USD in contracts to Regeneron Pharmaceuticals (REGN) in fiscal 2026, the year to 30 Sep 2026.
USAspending.gov
| Fiscal year | Committed |
|---|---|
| Fiscal 2026 (Oct 2025 to Sep 2026) | 279.4M USD |
| Fiscal 2023 (Oct 2022 to Sep 2023) | 326.5M USD |
Contracts of US$100,000 or more signed since April 2022; the amount is what the government has committed so far, which grows when options are exercised. Defense Department contracts are published about 90 days after signing, so the latest year is still filling in.
What has been filed or recorded for Regeneron Pharmaceuticals (REGN)?
The filings we hold for Regeneron Pharmaceuticals, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 61 shares | 50K USD notional · <0.001% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 52 shares | 42K USD notional · <0.001% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 6 shares | 5K USD notional · <0.001% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 12 shares | 10K USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 74 shares | 59K USD notional · <0.001% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 8 shares | 6K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 18.45 USD | |
| 30 Sep 2026 | Financials | Total assets | 44.4B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 33.5B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 12.23 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 6.75 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 41.48 USD | |
| 31 Dec 2025 | Financials | Revenue | 14.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 4.5B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 41.48 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 13.62 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 12.81 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 7.27 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 38.34 USD |
What is Reddit saying about Regeneron Pharmaceuticals (REGN)?
Reddit mentioned REGN 7 times in the 30 days to 22 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 22 November 2026.
30-day window, Method
How do Reddit mentions of Regeneron Pharmaceuticals (REGN) compare with its price?
Share ↗
Which subreddits are talking about Regeneron Pharmaceuticals (REGN)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 7 | +0.18 |
What do people ask about Regeneron Pharmaceuticals (REGN)?
What did Regeneron Pharmaceuticals shares close at?921.31
Regeneron Pharmaceuticals closed at 921.31 USD on 20 Nov 2026, down 0.25% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Regeneron Pharmaceuticals’ market cap?97.9B
Regeneron Pharmaceuticals is worth 97.9B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Regeneron Pharmaceuticals’ P/E ratio?20.4
Regeneron Pharmaceuticals has a price-to-earnings ratio of 20.4, as of 20 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Regeneron Pharmaceuticals’ revenue?14.3B
Regeneron Pharmaceuticals reported revenue of 14.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Regeneron Pharmaceuticals insiders bought or sold shares recently?16 sales
In the 90 days to 23 Nov 2026, Regeneron Pharmaceuticals insiders reported 16 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 10 Aug 2026, show no open-market purchase. A further 17 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Regeneron Pharmaceuticals?15 of 45
15 of the 45 funds we track reported a Regeneron Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Citadel Advisors. See Funds
Have members of Congress traded Regeneron Pharmaceuticals?37 trades
Yes. 37 trades in Regeneron Pharmaceuticals appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 15 May 2026, filed 8 Jun 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Regeneron Pharmaceuticals last report earnings?18.45
Regeneron Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 18.45 USD; no next date is announced in SEC filings yet. See Filings
Does Regeneron Pharmaceuticals have government contracts?279.4M
Yes. US federal agencies committed 279.4M USD in contracts to it in fiscal 2026, the year to 30 Sep 2026 (USAspending.gov). See Contracts
What is Reddit saying about Regeneron Pharmaceuticals?0 mentions
Regeneron Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 7 times over the trailing 30 days. Of the 7 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Byron Donalds: United States Congress, Public domain; Jefferson Shreve: House Creative Services, Public domain; Robert P. Bresnahan, Jr.: House Creative Services, Public domain; Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- USAspendingUSAspending.gov (U.S. Department of the Treasury), federal prime contract awards
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals